Phase II Trial for the Treatment of Recurrent or Persistent Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With Gemcitabine and Topotecan
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Gemcitabine; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2010 Biomarkers information updated
- 20 Sep 2010 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
- 20 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.